| __timestamp | Merus N.V. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 2917513 |
| Thursday, January 1, 2015 | 839656 | 7878291 |
| Friday, January 1, 2016 | 4478145 | 8366794 |
| Sunday, January 1, 2017 | 16432324 | 6610381 |
| Monday, January 1, 2018 | 11890871 | 6556000 |
| Tuesday, January 1, 2019 | 34110000 | 6930000 |
| Wednesday, January 1, 2020 | 35781000 | 8758000 |
| Friday, January 1, 2021 | 40896000 | 10806000 |
| Saturday, January 1, 2022 | 52200000 | 9844000 |
| Sunday, January 1, 2023 | 59836000 | 13481000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Merus N.V. and Soleno Therapeutics, Inc. from 2014 to 2023. Over this period, Merus N.V. has seen a staggering increase in SG&A expenses, growing by approximately 1,450%, from $3.85 million in 2014 to nearly $59.84 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Soleno Therapeutics, Inc. has maintained a more stable trajectory, with a 362% increase, reaching $13.48 million in 2023. This steady growth suggests a more conservative approach to scaling operations. These trends highlight the differing strategic priorities of these companies, offering insights into their market positioning and future potential.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared